Veradermics Publishes Study 302 Part B Phase 3 Hair Loss Data Presentation

• Veradermics published its Study 302 Part B presentation reporting 12-month Phase 3 results for VDPHL01 in men with mild-to-moderate pattern hair loss.
• Non-vellus hair counts increased by 29.7 hairs/cm² with 8.5 mg once-daily dosing versus 43.9 hairs/cm² with twice-daily dosing at 12 months.
• Hair coverage improvement was reported by 79.8% of once-daily recipients versus 89.1% of twice-daily recipients.
• Continued treatment produced no treatment-related serious adverse events or cardiac adverse events of special interest.
• No adverse-event-related discontinuations occurred in the continued-treatment group during Part B.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.